High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer.
BACKGROUND
High-risk non-muscle-invasive bladder cancer (NMIBC) remains challenging given the high probability of progression. Given that the androgen receptor (AR) has been discussed as a possible factor in the development and progression of bladder cancer, we investigated the predictive value of AR in stage pT1 NMIBC.


METHODS
We retrospectively analyzed the clinical data and AR mRNA expression in 296 patients with stage pT1 NMIBC who underwent a transurethral resection of the bladder. The mRNA expression of the AR transcript variants 1 (AR1) and 2 (AR2) was measured by reverse transcription quantitative real-time polymerase chain reaction. AR expression was also correlated to KRT5 and KRT20 mRNA expression.


RESULTS
Kaplan-Meier analysis indicated that high AR1 mRNA expression ≥35.47 is associated with statistically significant better recurrence-free survival (RFS) (P=.0007), progression-free survival (PFS) (P=.0420), and cancer-specific survival (CSS) (P=.0050). Multivariate Cox regression analysis revealed that high AR1 mRNA expression is an independent prognostic marker for RFS (P=.0029) and CSS (P=.0119). Spearman rank correlation revealed a significant positive association between mRNA expression of AR1 and KRT5 (rs: 0.3171, P<.0001) as well as a negative association with multifocal tumors (rs: 0.1478, P<.0109). No association was noted between AR1 expression and tumor grade, concomitant CIS, gender, tumor size, and KRT20 in patients with stage T1 NMIBC.


CONCLUSIONS
AR mRNA expression can predict RFS and CSS in patients with stage T1 NMIBC. Further studies are necessary to refine the relevance of AR mRNA expression compared with immunohistochemically detectable AR expression.
Department of Urology, University Hospital Erlangen, Erlangen, Germany. Electronic address: danijel.sikic@uk-erlangen.de.
Danijel
D
Sikic
Department of Urology, University of Regensburg, Regensburg, Germany. Electronic address: johannes.breyer@ukr.de.
Johannes
J
Breyer
Institute of Pathology, University Hospital Erlangen, Erlangen, Germany. Electronic address: arndt.hartmann@uk-erlangen.de.
Arndt
A
Hartmann
Department of Urology, University of Regensburg, Regensburg, Germany. Electronic address: maximilian.burger@ukr.de.
Maximilian
M
Burger
Department of Urology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. Electronic address: philipp.erben@medma.uni-heidelberg.de.
Philipp
P
Erben
Department of Urology, University of Regensburg, Regensburg, Germany. Electronic address: stefan.denzinger@ukr.de.
Stefan
S
Denzinger
Institute of Pathology, University Hospital Erlangen, Erlangen, Germany. Electronic address: markus.eckstein@uk-erlangen.de.
Markus
M
Eckstein
Institute of Pathology, University Hospital Erlangen, Erlangen, Germany. Electronic address: robert.stoehr@uk-erlangen.de.
Robert
R
Stöhr
Department of Urology, University Hospital Erlangen, Erlangen, Germany. Electronic address: sven.wach@uk-erlangen.de.
Sven
S
Wach
Department of Urology, University Hospital Erlangen, Erlangen, Germany. Electronic address: bernd.wullich@uk-erlangen.de.
Bernd
B
Wullich
Department of Urology, University Hospital Erlangen, Erlangen, Germany. Electronic address: bastian.keck@uk-erlangen.de.
Bastian
B
Keck
STRATIFYER Molecular Pathology GmbH, Cologne, Germany. Electronic address: ralph.wirtz@STRATIFYER.de.
Ralph M
RM
Wirtz
Department of Urology, University of Regensburg, Regensburg, Germany. Electronic address: wolfgang.otto@ukr.de.
Wolfgang
W
Otto